甲状腺激素减停的临床方法
甲状腺激素过度使用普遍,左甲状腺素是美国最常处方药之一,许多患者因轻度亚临床甲减或无证据适应症开始用药。高确定性证据未显示亚临床甲减患者起始甲状腺激素在生活质量等症状上获益,且治疗有负担、危害和费用,但多数患者一旦起始便终身使用。减停是一种结构化循证方法,近期有限数据支持在选定患者中可行安全,本文通过3例说明其原理与关键考虑。
要点
- 亚临床甲减起始甲状腺激素缺乏高确定性获益证据
- 左甲状腺素常被终身使用,需主动识别可减停者
- 减停需结构化、以患者为中心并密切监督
核心结论
- 在临床适当时,应通过结构化减停减少不必要的甲状腺激素治疗。
研究设计与样本
- 本文为临床方法学文章,包含3例服用左甲状腺素的 illustrative 病例。
主要发现
- 高确定性证据未显示亚临床甲减患者起始甲状腺激素在生活质量、甲减症状等重要结局上获益。
- 甲状腺激素治疗与潜在患者负担、危害和费用相关。
- 多数患者一旦起始左甲状腺素便终身继续使用。
- 近期有限数据支持在选定患者中甲状腺激素减停的可行性和安全性。
临床怎么用
- 对临床适当者制定结构化、以患者为中心且密切监督的减停计划。
- 识别并处理临床医生、患者和系统层面的减停障碍与促进因素。
局限性
- 支持减停的近期数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is widespread and increasing thyroid hormone overuse. Levothyroxine, a synthetic form of thyroid hormone, is one of the most prescribed medications in the United States. Many patients are started on levothyroxine for the treatment of mild subclinical hypothyroidism or nonevidence-based indications (eg, euthyroid individuals with weight gain or depression). High-certainty evidence does not show a benefit of thyroid hormone initiation in important patient outcomes (eg, quality of life, hypothyroid symptoms) for patients with subclinical hypothyroidism. Moreover, thyroid hormone treatment is associated with potential patient burden, harms, and costs. Yet, once levothyroxine is initiated, it is continued lifelong for most patients. Therefore, active interventions are needed to reduce unnecessary thyroid hormone treatment when it is clinically appropriate. Deprescribing is a structured and evidence-based approach to safely taper or discontinue unnecessary or potentially inappropriate medications, aiming to reduce polypharmacy, improve outcomes, and decrease health care costs and patient harm. Recent limited data support the feasibility and safety of thyroid hormone deprescribing in selected patients and describe clinician-, patient-, and system-level barriers and facilitators to implementing this intervention. We present 3 illustrative clinical cases of patients taking levothyroxine to exemplify the rationale and key considerations in thyroid hormone deprescribing, emphasizing that a structured, patient-centered, and closely supervised plan is essential for safe and effective thyroid hormone deescalation in clinically appropriate situations.
引用
- Maraka S, Papaleontiou M. Approach to the Patient Considering Thyroid Hormone Deprescribing. J Clin Endocrinol Metab. 2026. PMID: 41482002. doi:10.1210/clinem/dgaf697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。